Cargando…

Hypothyroidism Is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy

SIMPLE SUMMARY: Patients with advanced hepatocellular carcinoma (HCC) undergoing molecular targeted therapy often experience non-negligible adverse events (AEs). Paradoxically, certain AEs are reportedly associated with a good prognosis. We aimed to identify factors predictive of treatment duration...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shomura, Masako, Okabe, Haruka, Sato, Emi, Fukai, Kota, Shiraishi, Koichi, Hirose, Shunji, Tsuruya, Kota, Arase, Yoshitaka, Anzai, Kazuya, Kagawa, Tatehiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690372/ https://www.ncbi.nlm.nih.gov/pubmed/33105621 http://dx.doi.org/10.3390/cancers12113078

Ejemplares similares

Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment
por: Shomura, Masako, et al.
Publicado: (2016)

Complete Response after Short-Term Sorafenib Treatment in a Patient with Lymph Node Metastasis of Hepatocellular Carcinoma
por: Mizukami, Hajime, et al.
Publicado: (2012)

Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B
por: Nagata, Naruhiko, et al.
Publicado: (2016)

Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
por: Arase, Yoshitaka, et al.
Publicado: (2018)

Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients
por: Hirose, Shunji, et al.
Publicado: (2020)

Efficacy and Safety of 3‐Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases
por: Arase, Yoshitaka, et al.
Publicado: (2019)

Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Arase, Yoshitaka, et al.
Publicado: (2019)

Successful Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices Using Foam Sclerosant Followed by Glue Embolization of Gastrorenal Shunt via the Brachial Vein Approach in a Severely Obese Patient
por: Tsuruya, Kota, et al.
Publicado: (2019)

The prevalence and natural history of hepatic cysts examined by ultrasound: a health checkup population retrospective cohort study
por: Tsuruya, Kota, et al.
Publicado: (2022)

First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan
por: Tsuruya, Kota, et al.
Publicado: (2023)

Kruppel-like factor 15 induces the development of mature hepatocyte-like cells from hepatoblasts
por: Anzai, Kazuya, et al.
Publicado: (2021)

Rapid Regression of B-Cell Non-Hodgkin's Lymphoma after Eradication of Hepatitis C Virus by Direct Antiviral Agents
por: Hirose, Shunji, et al.
Publicado: (2019)

Loss of organic anion transporting polypeptide 1B3 function causes marked delay in indocyanine green clearance without any clinical symptoms
por: Kagawa, Tatehiro, et al.
Publicado: (2017)

Foetal hepatic progenitor cells assume a cholangiocytic cell phenotype during two-dimensional pre-culture
por: Anzai, Kazuya, et al.
Publicado: (2016)

Intussusception due to hematogenous metastasis of hepatocellular carcinoma to the small intestine: A case report
por: Mashiko, Taro, et al.
Publicado: (2020)

Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting
por: Fukushima, Taito, et al.
Publicado: (2021)

A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

Safety and Efﬁcacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis
por: Ogushi, Katsuaki, et al.
Publicado: (2020)

Reply:
por: Arase, Yoshitaka, et al.
Publicado: (2020)

Reply:
por: Arase, Yoshitaka, et al.
Publicado: (2020)

Relationship between response to lusutrombopag and splenic volume
por: Uojima, Haruki, et al.
Publicado: (2018)

Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Fukushima, Taito, et al.
Publicado: (2023)

Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment
por: Chuma, Makoto, et al.
Publicado: (2022)

A case of incomplete duplication of the portal vein associated with multiple congenital anomalies
por: Ichikawa, Tamaki, et al.
Publicado: (2023)

Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma
por: Imakura, Takeshi, et al.
Publicado: (2021)

Hypothyroidism in metabolic syndrome
por: Kota, Sunil Kumar, et al.
Publicado: (2012)

Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
por: Chuma, Makoto, et al.
Publicado: (2020)

A case of breast cancer with extensive colon metastasis
por: Imai, Jin, et al.
Publicado: (2022)

Optimal use of lenvatinib in the treatment of advanced thyroid cancer
por: Takahashi, Shunji, et al.
Publicado: (2017)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

A Case of Unresectable Combined Hepatocellular-Cholangiocarcinoma Successfully Treated with Lenvatinib
por: Osuga, Takahiro, et al.
Publicado: (2022)

Validation of self‐reported medication use for hypertension, diabetes, and dyslipidemia among employees of large‐sized companies in Japan
por: Fukai, Kota, et al.
Publicado: (2020)

Usefulness of autotaxin for the complications of liver cirrhosis
por: Shao, Xue, et al.
Publicado: (2020)

Differential Impact of Adherence to Pegylated Interferon and Ribavirin in the Treatment of Genotype 1 High Viral Titer Chronic Hepatitis C
por: Numata, Makoto, et al.
Publicado: (2010)

Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan
por: Takahashi, Shunji, et al.
Publicado: (2020)

Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers
por: Suyama, Koichi, et al.
Publicado: (2018)

Management of severe hypertension due to lenvatinib in patients with advanced thymic carcinoma: A case report
por: Matsumoto, Kinnosuke, et al.
Publicado: (2022)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma
por: Tateai, Yoshikazu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_htipvpaiucfqiv6r0rrr5q5qot